Clinical Trial Update: Trametinib for Pediatric Neuro-oncology Patients With Refractory Tumor and Activation of the MAPK/ERK Pathway. [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating trametinib in pediatric neuro-oncology patients with refractory tumors showing MAPK/ERK pathway activation. The conditions inc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Glioma
• Low-grade Glioma
• Plexiform Neurofibroma

Drugs mentioned

• Trametinib (trametinib)

Snippet

Sponsor: St. Justine's Hospital | Conditions: Low-grade Glioma, Plexiform Neurofibroma | Phase 2 | Status: ACTIVE_NOT_RECRUITING